Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.25 - $170.47
Previous CloseN/A
Volume7.58M
Average Volume (3M)11.15M
Market Cap
$12.52B
Enterprise Value$21.15B
Total Cash (Recent Filing)$1.93B
Total Debt (Recent Filing)$710.00M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 01, 2025EPS Estimate
-3.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.28
Shares Outstanding385,815,900
10 Day Avg. Volume8,258,877
30 Day Avg. Volume11,147,479
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.87
Price to Cash Flow (P/CF)3.80
P/FCF Ratio3.70
Enterprise Value/Market Cap1.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.94
Enterprise Value/Ebitda-6.23
Forecast
1Y Price Target
$41.75Price Target Upside27.83% Upside
Rating ConsensusHold
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Cost Reduction StrategyThe company expects a $1 billion reduction in cash costs from 2024 to 2025, which contributes to the goal of cash breakeven by 2028.
Pipeline ProspectsPotential approvals in 2025, as well as higher vaccination rates and improved competitive positioning, could provide upside to revenue guidance.
Bears Say
Patent LitigationGenevant and Arbutus are seeking monetary relief and injunctions against Spikevax and additional Moderna products that use the same LNP technology.
Product Launch ChallengesTwo new setbacks disclosed: the norovirus vaccine program is now on 'clinical hold' by FDA and the combo flu+COVID program will require Moderna to demonstrate vaccine efficacy of the stand-alone flu component before approval can occur.
Revenue DeclineModerna is aiming to enhance its pipeline to drive revenues to offset the fall in Spikevax sales, however these efforts have been too little too late, as total revenue has fallen >60% y/y in FY23 with no product immediately available to carry on driving revenues.
---
Ownership Overview
18.59% Insiders
19.87% Mutual Funds
21.50% Other Institutional Investors
16.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $29.25 and its highest was $170.47 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $12.52B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is May 01, 2025 which is in 39 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Feb 14, 2025. The company reported -$2.91 earnings per share for the quarter, missing the consensus estimate of -$2.68 by -$0.23.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -3.08.
How many shares outstanding does Moderna have?
Moderna has 385,815,900 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$2.91 in its last earnings report, missing expectations of -$2.68. Following the earnings report the stock price went up 3.352%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
---
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$41.75 (27.83% Upside)
$41.75 (27.83% Upside)
Blogger Sentiment
Bullish
MRNA Sentiment 68%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 326.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.62%
12-Months-Change
Fundamentals
Return on Equity
-28.77%
Trailing 12-Months
Asset Growth
-23.25%
Trailing 12-Months
Company Description
Moderna
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
---
MRNA Company Deck
---
MRNA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Moderna's earnings call reflected a challenging year with significant revenue declines and net losses. However, the company demonstrated strong cost-saving measures and maintained a substantial cash position. Progress in the product pipeline and operational efficiency goals offer potential for future growth.Read More>---
MRNA Revenue Breakdown
55.16% U.S.
26.36% Rest of World
18.48% Europe
---
MRNA Stock 12 Month Forecast
Average Price Target
$41.75
▲(27.83% Upside)
Technical Analysis
Best Analysts Covering MRNA
1 Year
1 Year Success Rate
9/34 ratings generated profit
1 Year Average Return
-3.50%
reiterated a buy rating 2 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 26.47% of your transactions generating a profit, with an average return of -3.50% per trade.
---